DENG, Liang,SHUMAN, Stewart,WOLCHOK, Jedd,MERGHOUB, Taha,WANG, Weiyi,DAI, Peihong,YANG, Ning
申请号：
SG11201807022X
公开号：
SG11201807022XA
申请日:
2017.02.25
申请国别(地区):
SG
年份:
2018
代理人:
摘要：
The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.
